The term ‘female sexual dysfunction’ (FSD) encompasses a number of different disorders, and while their aetiologies are not fully understood, the sub-classifications of this broad umbrella term are increasingly becoming more established and accepted. However, there is less consensus regarding the optimal treatment of these conditions. While it is known that phosphodiesterase (PDE5) is involved in the female sexual response, the clinical and research evidence supporting the unlicensed use of PDE5 inhibitors (PDE5i) in women is inconclusive and at times contradictory. In this article we explore this further by means of a comprehensive literature review on the use of PDE5i in the treatment of FSD and we also present our clinical experience of using these drugs in this context.
NazarethI, BoyntonP, KingM. Problems with sexual function in people attending London general practitioners: cross sectional study. BMJ2003;327:423
2.
LaumannEO, PaikA, RosenRC. Sexual dysfunction in the United States. JAMA1999;281:537–45
3.
DunnKM, CroftPR, HackettGI. Sexual Problems: a study of the prevalence and need for health care in the general population. Fam Pract1998;15:519–24
4.
MercerCH, FentonKA, JohnsonAM, Sexual function problems and help seeking behaviour in Britain: national probability sample survey. BMJ2003;327:426–7
5.
HayesRD, DennersteinL, BennettCM, FairleyCK. What is the true prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact?J Sex Med2008;5:777–87
6.
BassonR, LeiblumS, BrottoL, Revised definitions of women's sexual dysfunction. J Sex Med2004;1:40–8
7.
KaplanHS. Disorders of Sexual Desire. New York: Brunner/Mazel, 1979
8.
ParkK, MorelandRB, GoldsteinI, AtalaA, TraishA. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernous smooth muscle. Biochem Biophys Res Commun1998;249:612–7
9.
UckertS, MayerME, JonasU, StiefCG. Immunohistochemical presence of cyclicAMP and cyclicGMP phosphodiesterase isoenzymes in the human clitoris (abstract). Eur Urol2003;1:118
10.
D'amatiG, diGioiaCRT, BolognaM, Type 5 phosphodiesterase expression in the human vagina. Urology2002;60:191–5
11.
BurnettAL, CalvinDC, SilverRI, PeppasDS, DocimoSG. Immunohistochemical description of nitric oxide synthetase isoforms in the human clitoris. J Urol1997;158:75–8
12.
LeiblumSR, ChiversML. Normal and persistent genital arousal in women: new perspectives. J Sex Mar Ther2007;33:357–73
13.
KaplanSA, ReisRB, JohnIJ, Safety and Efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology1999;53:481–6
14.
NurnbergHG, LaurielloJ, HensleyPL, ParkerLM, KeithSJ. Sildenafil for sexual dysfunction in women taking antidepressants. Am J Psychiatry1999;156:1664–5
15.
BermanJR, BermanLA, LinH, FlahertyE, LaheyN, GoldsteinI. Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. J Sex Mar Ther2001;28:411–20
16.
BermanLA, BermanJR, BruckD, PawarRV, GoldsteinI. Pharmacotherapy or psychotherapy?: Effective treatment for FSD related to unresolved childhood sexual abuse. J Sex Mar Ther2001;27:421–5
17.
AtalasE, YagciB. The effect of sildenafil citrate on uterine and clitoral arterial blood flow in postmenopausal women. Med Gen Med2004;6:51
18.
RichardsonD, GoldmeierD, KocsisA. PDE5 inhibitors may help some women with sexual problems. Sex Relations Ther2005;20:65–9
19.
FerraraD, ZaslauS. Success of sildenafil treatment in neurogenic female sexual dysfunction caused by L5-S1 intervertebral disk rupture: a case report. Int J Urol2007;14:566–8
20.
RosenRC. Sexual function assessment and the role of vasoactive drugs in female sexual dysfunction. Arch Sex Behav2002;31:439–43
21.
GoldsteinI, LueTF, Padma-NathanH, Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med1998;338:1397–404
22.
SipskiML, RosenRC, AlexanderCJ, HamerRM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology2000;55:812–5
23.
CarusoS, IntelisanoG, LupoL, AgnelloC. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obstet Gynaecol2001;108:623–8
24.
LaanE, Van LunsinRHW, EveraerdW, The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. J Women Health Gender Based Med2002;11:357–65
25.
BassonR, McInnesR, SmithMD, HodgsonG, KoppikerN. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Women Health Gender Based Med2002;11:367–77
26.
CarusoS, IntelisanoG, FarinaM, Di MariL, AgnelloC. The function of sildenafil on female sexual pathways: a double-blind, cross-over, placebo-controlled study. Eur J Obstet Gynaecol Reprod Biol2003;110:201–6
27.
BassonR, BrottoLA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. Br J Obstet Gynaecol2003;110:1014–24
28.
BermanJR, BermanLA, TolerSM, GillJ, HaughieS. Safety and Efficacy of sildenafil citrate for the treatment of female sexual arousal disorder. J Urol2003;170:2333–8
29.
DasguptaR, WisemnG, KanabarG, FowlerC. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol2004;171:1189–93
30.
CarusoS, RugoloS, AgnelloC, IntelisanoG, Di MariL, CianciA. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril2006;85:1496–501
31.
ClaretL, CoxEH, McFaydenL, Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate. Pharm Res2006;23:1756–64
32.
YangCC, CaoYY, GuanQY, Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating a drug response. Int J Impot Res2008;20:105–10
33.
NurnbergHG, HensleyPL, HeinmanJR, CroftHA, DebattistaC, PaineS. Sildenafil treatment of women with antidepressant-associated sexual dysfunction. JAMA2008;300:395–404
34.
MoynihanR. The making of a disease: female sexual dysfunction. BMJ2003;326:45–7
35.
BancroftJ, LoftusJ. Scott Long. Distress about sex: a national survey of women in heterosexual relationships. Arch Sex Behav2003;32:193–208
36.
BrinkCB, ClaptonJD, EagarBE, HarveyBH. Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm2008;115:117–25
37.
OrrG, SeidmanSN, WeiserM, GershonAA, DubrovY, KleinDF. An open-label pilot study to evaluate the efficacy of sildenafil citrate in middle-aged men with late-onset dysthymia. J Nerv Ment Dis2008;196:496–500
38.
KayaC, YilmazG, NurkalemZ, IlktacA, KaramanMI. Sexual function in women with coronary artery disease: a preliminary study. Int J Impot Res2007;19:326–9
39.
DerzkoC, ElliottS, LamW. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol2007;14:S20–40
40.
FavaM, NurnbergHG, SeidmanSN, Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry2006;67:240–6
41.
LabbateLA, CroftHA, OleshanskyMA. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. J Clin Psychiatry2003;64:11–9
42.
BernerMM, HagenM, KristonL. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev2007;24:CD003546
